Crepaldi G, Fioretto P
Department of Medical and Surgical Sciences, University of Padova, Italy.
Metabolism. 2000 Oct;49(10 Suppl 2):21-5. doi: 10.1053/meta.2000.17826.
The constraints of intensive multifactorial management of type 2 diabetes dictate a need for effective, well-tolerated agents with simple administration regimens. Sulfonylureas remain the most frequently used agents, and represent a rational approach when consideration is given to the pathophysiology of this common condition. Trials of gliclazide modified release in varied populations have yielded very acceptable clinical results that support its first-line use in type 2 diabetes, including obese, elderly, and mild-to-moderate renal insufficient patients. The simplicity of its dose regimen and its efficacy and tolerance profile may significantly contribute to improving compliance.
2型糖尿病强化多因素管理的限制表明，需要有效、耐受性良好且给药方案简单的药物。磺脲类药物仍然是最常用的药物，从这种常见疾病的病理生理学角度考虑，这是一种合理的治疗方法。在不同人群中进行的格列齐特缓释片试验产生了非常理想的临床结果，支持其在2型糖尿病患者（包括肥胖、老年以及轻度至中度肾功能不全患者）中作为一线用药。其给药方案的简单性以及疗效和耐受性特点可能对提高依从性有显著帮助。
